iproniazid and phentermine

iproniazid has been researched along with phentermine in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Seiler, KU; Wasserman, O1
Opitz, K; Weischer, ML1
Maher, TJ; Ulus, IH; Wurtman, RJ1

Reviews

1 review(s) available for iproniazid and phentermine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for iproniazid and phentermine

ArticleYear
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
MAO-inhibitory properties of anorectic drugs.
    The Journal of pharmacy and pharmacology, 1973, Volume: 25, Issue:7

    Topics: Animals; Appetite Depressants; Chlorphentermine; Dose-Response Relationship, Drug; Hypertension, Pulmonary; In Vitro Techniques; Iproniazid; Lung; Methysergide; Mitochondria, Liver; Monoamine Oxidase Inhibitors; Oxazoles; Phenmetrazine; Phentermine; Rats; Serotonin Antagonists

1973
[The excretion of anorectic phenylalkylamines in the urine].
    Arzneimittel-Forschung, 1966, Volume: 16, Issue:10

    Topics: Animals; Appetite Depressants; Carbamates; Chlorphentermine; Chromatography, Thin Layer; Fenfluramine; Fluorine; Iproniazid; Male; Phenethylamines; Phentermine; Rats

1966
Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors.
    Biochemical pharmacology, 2000, Jun-15, Volume: 59, Issue:12

    Topics: Animals; Antidepressive Agents; Brain; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Interactions; Ephedrine; Iproniazid; Liver; Lung; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phentermine; Rats; Rats, Sprague-Dawley

2000